Immunotherapy drug shows promise for rare, aggressive thyroid cancer
NCT ID NCT05119296
First seen Jan 08, 2026 · Last updated May 24, 2026 · Updated 34 times
Summary
This study tests the drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer that cannot be cured by standard treatments. The goal is to see if the drug can shrink or stop the cancer. Participants receive the drug every 3 weeks until the cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.